BET bromodomain inhibition synergizes with PARP inhibitor in epithelial ovarian cancer

PARP inhibition is known to be an effective clinical strategy in BRCA-mutant cancers, but PARP inhibition has not been applied to BRCA-proficient tumors. Here we show synergy of BET bromodomain inhibition with PARP inhibition in BRCA-proficient ovarian cancers due to mitotic catastrophe. Treatment o...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cell Rep
Päätekijät: Karakashev, Sergey, Zhu, Hengrui, Yokoyama, Yuhki, Zhao, Bo, Fatkhutdinov, Nail, Kossenkov, Andrew V., Wilson, Andrew J., Simpkins, Fiona, Speicher, David, Khabele, Dineo, Bitler, Benjamin G., Zhang, Rugang
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2017
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5745042/
https://ncbi.nlm.nih.gov/pubmed/29262321
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.celrep.2017.11.095
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia